Wall Street Zen Upgrades LifeStance Health Group (NASDAQ:LFST) to “Buy”

LifeStance Health Group (NASDAQ:LFST) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Friday.

LFST has been the topic of a number of other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of LifeStance Health Group in a research note on Monday, December 29th. UBS Group upped their price target on shares of LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Barclays assumed coverage on shares of LifeStance Health Group in a report on Tuesday, December 9th. They set an “overweight” rating and a $8.00 price objective on the stock. BMO Capital Markets assumed coverage on shares of LifeStance Health Group in a research note on Thursday, November 13th. They issued an “outperform” rating and a $8.00 target price for the company. Finally, BTIG Research boosted their price objective on shares of LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.83.

LifeStance Health Group Price Performance

NASDAQ:LFST opened at $7.34 on Friday. The company has a quick ratio of 1.58, a current ratio of 1.58 and a debt-to-equity ratio of 0.18. The firm has a market cap of $2.86 billion, a PE ratio of -244.67 and a beta of 1.12. LifeStance Health Group has a 12 month low of $3.74 and a 12 month high of $8.30. The company’s 50-day moving average price is $6.88 and its two-hundred day moving average price is $5.72.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.03. LifeStance Health Group had a negative net margin of 0.67% and a negative return on equity of 0.62%. The company had revenue of $363.81 million during the quarter, compared to analyst estimates of $355.06 million. During the same quarter last year, the business posted ($0.02) earnings per share. The company’s revenue was up 16.3% on a year-over-year basis. On average, equities analysts anticipate that LifeStance Health Group will post -0.18 EPS for the current fiscal year.

Insider Activity

In other LifeStance Health Group news, insider Lisa K. Miller sold 57,240 shares of the stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $6.43, for a total value of $368,053.20. Following the completion of the sale, the insider directly owned 261,292 shares in the company, valued at $1,680,107.56. This represents a 17.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Robert Bessler sold 119,942 shares of the firm’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $7.04, for a total value of $844,391.68. Following the sale, the director directly owned 1,318,983 shares in the company, valued at approximately $9,285,640.32. This represents a 8.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 327,326 shares of company stock valued at $2,259,317 in the last quarter. Company insiders own 3.20% of the company’s stock.

Institutional Trading of LifeStance Health Group

Large investors have recently bought and sold shares of the business. Park Edge Advisors LLC boosted its holdings in shares of LifeStance Health Group by 14.4% during the 4th quarter. Park Edge Advisors LLC now owns 11,863 shares of the company’s stock worth $84,000 after buying an additional 1,495 shares during the period. Vident Advisory LLC lifted its holdings in shares of LifeStance Health Group by 12.7% during the second quarter. Vident Advisory LLC now owns 21,732 shares of the company’s stock worth $112,000 after buying an additional 2,447 shares in the last quarter. State of Wyoming boosted its position in shares of LifeStance Health Group by 3.8% in the third quarter. State of Wyoming now owns 89,927 shares of the company’s stock valued at $495,000 after acquiring an additional 3,298 shares during the period. Legal & General Group Plc grew its stake in shares of LifeStance Health Group by 2.4% in the second quarter. Legal & General Group Plc now owns 144,263 shares of the company’s stock valued at $746,000 after acquiring an additional 3,331 shares in the last quarter. Finally, Polar Capital Holdings Plc grew its stake in shares of LifeStance Health Group by 19.3% in the third quarter. Polar Capital Holdings Plc now owns 21,775 shares of the company’s stock valued at $120,000 after acquiring an additional 3,525 shares in the last quarter. 85.50% of the stock is owned by institutional investors.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.